Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,881 to 2,900 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE) | 93 of 1,264 77 of 1,279 | 1.3 points -0.6 to 3.3 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 77 of 1,264 68 of 1,279 | 0.8 points -1.0 to 2.6 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular) | 10 of 1,264 11 of 1,279 | -0.1 points -0.8 to 0.7 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI) | 71 of 1,264 56 of 1,279 | 1.2 points -0.5 to 3.0 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 80 of 1,264 72 of 1,279 | 0.7 points -1.2 to 2.6 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 54 of 1,264 39 of 1,279 | 1.2 points -0.2 to 2.7 | 2,543 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Dabigatran 150 mg vs Warfarin: serious adverse events | 165 of 1,273 150 of 1,266 | 1.1 points -1.5 to 3.7 | 2,539 | NCT00291330 Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism |
| Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography | 71 of 1,259 87 of 1,270 | -1.2 points -3.1 to 0.7 | 2,529 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Transdisciplinary Approach vs Multidisciplinary Approach: Dispensing of Psychotropic Medications | 161 of 742 315 of 1,787 | 4.1 points 0.7 to 7.6 | 2,529 | NCT03442322 Optimizing Care for Patients With Dementia |
| Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR) | 22 of 1,255 20 of 1,273 | 0.2 points -0.8 to 1.2 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF) | 98 of 1,255 83 of 1,273 | 1.3 points -0.7 to 3.3 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR) | 125 of 1,255 114 of 1,273 | 1.0 points -1.3 to 3.3 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Myocardial Infarction (MI) | 80 of 1,255 65 of 1,273 | 1.3 points -0.6 to 3.1 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR | 22 of 1,255 20 of 1,273 | 0.2 points -0.8 to 1.2 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE) | 102 of 1,255 89 of 1,273 | 1.1 points -0.9 to 3.2 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With All Coronary Revascularization | 64 of 1,255 51 of 1,273 | 1.1 points -0.5 to 2.8 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants With Target Lesion Failure (TLF) | 98 of 1,255 83 of 1,273 | 1.3 points -0.7 to 3.3 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI | 89 of 1,255 79 of 1,273 | 0.9 points -1.1 to 2.8 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI | 83 of 1,255 73 of 1,273 | 0.9 points -1.0 to 2.8 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
| Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF) | 111 of 1,255 101 of 1,273 | 0.9 points -1.3 to 3.1 | 2,528 | NCT02173379 Absorb IV Randomized Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=145"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=145
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02173379-7c14a724",
"title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)",
"summary": "93 of 1264 against 77 of 1279; risk difference 1.3 points, 95% interval -0.6 to 3.3; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-7c14a724",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2543,
"risk_difference": {
"value": 0.013372665551607765,
"lower": -0.006119210315356283,
"upper": 0.03300900186362439
},
"group_1": "93 of 1,264",
"group_2": "77 of 1,279",
"difference": "1.3 points",
"interval": "-0.6 to 3.3",
"trial_title": "Absorb IV Randomized Controlled Trial"
},
{
"id": "NCT02173379-b82ddd81",
"title": "Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI",
"summary": "77 of 1264 against 68 of 1279; risk difference 0.8 points, 95% interval -1.0 to 2.6; NCT02173379, Absorb IV Randomized Controlled Trial",
"record": "/library/comparisons/NCT02173379-b82ddd81",
"nct_id": "NCT02173379",
"kind": "outcome",
"participants": 2543,
"risk_difference": {
"value": 0.007751185162458804,
"lower": -0.010388179075993272,
"upper": 0.02600914219221606
},
"group_1": "77 of 1,264",
"group_2": "68 of 1,279",
"difference": "0.8 points",
"interval": "-1.0 to 2.6",
"trial_title": "Absorb IV Randomized Controlled Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=146",
"request_id": "AerknHzhXiVAuzA0"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant